[ { "id": 739, "name": "Notable Labs", "slug": "notable-labs", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/c2bf47d120c3bdde2a9ad11d9f05f1c08a72ca0e.png", "website": "http://notablelabs.com", "all_locations": "San Francisco, CA, USA; Foster City, CA, USA", "long_description": "Notable Labs is building a personalized drug discovery platform to identify treatment options for relapsed and refractory cancer patients — starting with blood cancer — to address the long tail of cancer treatment. We look at a person’s actual cancer cells, test combinations of FDA approved drugs, and see which combinations kill the cancer cells and leave the healthy cells alive. We focus on combinations because cancer is often difficult to target with just one drug and starting with a single drug can lead to resistant clones or relapse. We're building a highly automated lab in Foster City running on our custom software and are currently testing relapsed/refractory cancer patients as well as samples from a variety of pharma/biotech partnerships.\r\n\r\nhttps://www.notablelabs.com/careers", "one_liner": "Personalized drug discovery for blood cancer.", "team_size": 40, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1407578442, "tags": [ "Biotech", "Drug discovery", "Oncology" ], "tags_highlighted": [], "top_company": true, "isHiring": true, "nonprofit": false, "batch": "Winter 2015", "status": "Public", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": true, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/notable-labs", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2015/notable-labs.json", "year_founded": 2014, "city": "San Francisco", "country": "US", "linkedin_url": "", "x_url": "https://twitter.com/notablelabs", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/notable-labs-2", "github_url": "https://github.com/NotableLabs", "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/c2bf47d120c3bdde2a9ad11d9f05f1c08a72ca0e.png", "app_video_url": null, "dday_video_url": "https://bookface-images.s3.us-west-2.amazonaws.com/video_event/10/1427240098052-kikiobbw3fcx47vi-0fb11434a5aa7dfed43fbe66e4b7cb1c/657f6ab39a6ef44174d31a96ba482867.mp4?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIAQC4NIECABPQ2AHNW%2F20261020%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20261020T022629Z&X-Amz-Expires=3600&X-Amz-SignedHeaders=host&X-Amz-Signature=1ec308578ecc7d87fd1dac00354b1e5c47a8c16627905c134810ce30ed926a49", "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 69577, "full_name": "Matthew De Silva", "title": "Founder/CEO", "founder_bio": "", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/matthewdesilva/", "x_url": "https://twitter.com/MDe_Silva", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/9f6eebea28438330b0e1b0a312affcdf60fa89eb.jpg" }, { "user_id": 69576, "full_name": "Pete Quinzio", "title": "Founder", "founder_bio": "", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/peter-quinzio-26083a35", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/e95bef4a9fd59491bdf3fab81ee4a4fc89118bcf.jpg" } ], "jobs": [ { "id": 16239, "title": "Senior Software Engineer - Full Stack", "url": "https://www.ycombinator.com/companies/notable-labs/jobs/Ey5oHo8pO-senior-software-engineer-full-stack", "location": "Foster city, CA", "type": "Full-time", "role": "Engineering", "role_type": "Full stack", "salary_range": "", "equity_range": "", "experience": "3+ years", "visa": "US citizen/visa only", "skills": [ "Amazon Web Services (AWS)", "Django", "Git", "GraphQL", "JavaScript", "Python", "React", "Docker" ] }, { "id": 37703, "title": "Product Development Scientist / Senior Assay Development Scientist", "url": "https://www.ycombinator.com/companies/notable-labs/jobs/ti2HBnyyd-product-development-scientist-senior-assay-development-scientist", "location": "Foster City, CA", "type": "Full-time", "role": "Science", "role_type": "Laboratory", "salary_range": "", "equity_range": "", "experience": "6+ years", "visa": "US citizen/visa only", "skills": [] }, { "id": 37704, "title": "Principal Product Development Scientist", "url": "https://www.ycombinator.com/companies/notable-labs/jobs/kF9VM8qjw-principal-product-development-scientist", "location": "Foster City, CA", "type": "Full-time", "role": "Science", "role_type": "Laboratory", "salary_range": "", "equity_range": "", "experience": "11+ years", "visa": "US citizen/visa only", "skills": [] } ], "news": [ { "title": "Personalized cancer treatment startup Notable Labs nabs $40M Series B - MedCity News", "url": "https://medcitynews.com/2019/07/personalized-cancer-treatment-startup-notable-labs-nabs-40-million-series-b/", "date": "Jul 16, 2019" }, { "title": "Notable raises $40 million to personalize cancer drug regimens | VentureBeat", "url": "https://venturebeat.com/business/notable-raises-50-million-to-personalize-cancer-drug-regimens/", "date": "Jul 16, 2019" } ], "launches": [] }, { "id": 756, "name": "Numerion Labs", "slug": "numerion-labs", "former_names": [ "Atomwise" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/c3b218096497a702becc32895ca1b21c4cae78bd.png", "website": "https://www.numerionlabs.ai", "all_locations": "San Francisco, CA, USA", "long_description": "Numerion Labs is an AI-native company accelerating the discovery of life-saving medicines through the development and use of cutting-edge machine learning algorithms. The company unites computational chemistry, structural biology, and medicinal chemistry to pioneer the next generation of AI-driven drug discovery platforms.", "one_liner": "Artificial intelligence for drug discovery.", "team_size": 67, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1416219336, "tags": [ "AI-powered Drug Discovery", "Deep Learning", "Biotech", "Drug discovery", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2015", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/numerion-labs", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2015/numerion-labs.json", "year_founded": null, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/atomwise/", "x_url": "https://twitter.com/atomwiseinc", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/atomwise", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/c3b218096497a702becc32895ca1b21c4cae78bd.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 7359, "full_name": "Abraham Heifets", "title": "Founder/CEO", "founder_bio": "Founder and CEO of A Company in Stealth Mode. Previously, cofounded Atomwise, the first company to deploy deep learning for structure-based drug design ($220+ million in funding; 100 hires; signed $5B in total partnership value with Sanofi, Bayer, Eli Lilly, etc; ran largest AI-driven drug discovery experiment w/ 600+ researchers in 30 countries). Even more previous: PhD @ U of Toronto; inventor on 15 patents + applications; IBM Research; AI for Cornell’s world champion robotic soccer team.", "is_active": false, "linkedin_url": "https://www.linkedin.com/in/abrahamheifets/", "x_url": "https://twitter.com/AbeHeifets", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/571a64309f08a9ce37f2b403541f4d87c8410311.jpg" }, { "user_id": 10392, "full_name": "Alex Levy", "title": "Founder", "founder_bio": "Leveraging AI to revolutionize the physical sciences, Alex Levy is the CEO and co-founder of Atmo, the leading company integrating AI into global weather forecasting. Previously, he co-founded Atomwise (W15), a pioneering AI company in small molecule drug discovery, boasting over 800 active programs and $1 billion in pharmaceutical partnerships. An alumnus of the University of Toronto, he began his career by leading a computer vision research lab within the Computer Science Department.", "is_active": false, "linkedin_url": "ca.linkedin.com/in/levyalex", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/9d6b2d29f328539e24d2cb0bac16217cc3f8838b.jpg" }, { "user_id": 10399, "full_name": "Izhar Wallach", "title": "Founder", "founder_bio": "-", "is_active": false, "linkedin_url": "https://www.linkedin.com/pub/izhar-wallach/11/38/a04", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/0dd953a0f7260cfc91ec2e0021a7c37e4238d45d.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1665, "name": "Oncobox", "slug": "oncobox", "former_names": [ "Oncobox", "OncoBox" ], "small_logo_thumb_url": "/company/thumb/missing.png", "website": "http://oncobox.com", "all_locations": "Walnut, CA, USA", "long_description": "Oncobox believes that many late-stage cancer patients are dying prematurely because doctors lack a data-driven tool to help them decide which drugs currently on the market would most effectively fight individual patients’ specific cancers. That’s where Oncobox comes in. Oncobox is low-cost personalized genetic profiling to help doctors decide which drug to use. In a recent study conducted by leading cancer researchers in Europe and Asia on 900 patients with various late-stage cancers, Oncobox increased the effectiveness of targeted therapies from 25% to 64%.\r\n\r\nHow does Oncobox work? Over 150 targeted cancer drugs are currently on the market. But deciding which of these drugs to give to late-stage cancer patients is not a simple task. Cancer doctors are in a race against the clock. They don’t always know which medication will be most effective for their patients. Because these drugs are expensive and typically have significant side effects, they can’t just try them all. Because of these barriers, targeted cancer therapies are effective only 25% of the time, and 70% of patients with late-stage cancers die due to the toxic side effects of ineffective drugs.\r\n\r\nOncobox Dx analyses tumor DNA, RNA, and molecular pathways using algorithms to distinguish which molecular targets are the most crucial for individual cases. Doctors receive a clinically actionable report that shows them which drugs are likely to be most effective on the patient.\r\n\r\nWe actively seek partners from pharma, hospitals/clinicians, payers, and genomic centers. Feel free to contact us at hello@oncobox.com. \r\n\r\nOur team and the scientific advisory board consisting of leading scientists and researchers from UCLA, Stanford, Johns Hopkins University, Boston University, Tufts University, and Rutgers University.", "one_liner": "Finding the right cancer drug for each patient. ", "team_size": 11, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1493851252, "tags": [ "Drug discovery", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2017", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/oncobox", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2017/oncobox.json", "year_founded": null, "city": "Walnut", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/oncobox", "github_url": null, "logo_url": null, "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 187287, "full_name": "Andrew Garazha", "title": "Founder/CEO", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/garazha/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/b2fe9db2ae1be10198b1053682fb59ad55e404d0.jpg" }, { "user_id": 189703, "full_name": "Anton Buzdin", "title": "Founder/CSO", "founder_bio": null, "is_active": true, "linkedin_url": "https://www.linkedin.com/in/anton-buzdin-8284972", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/645b94e854eaa634f8ab2e93480e9e5f87488952.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1686, "name": "Cambridge Cancer Genomics", "slug": "cambridge-cancer-genomics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/53b0518d38ef7cc187360951dee976ad809db1d9.png", "website": "http://ccg.ai", "all_locations": "Cambridge, England, United Kingdom; England, United Kingdom", "long_description": "CCG.ai exist to ensure that each patient has the right drug, at the right time, to beat their cancer.\r\n‍\r\nWe build the software to enable data-driven precision oncology and systematically develop data-driven biomarkers indicative of treatment response. We believe that increasing amounts of clinical and genomic data have the potential to transform cancer treatment, and enable oncologists to make smarter decisions about which drug to use in which circumstance.\r\n\r\nWe are expanding our team in Cambridge, UK, offering a fantastic opportunity for dedicated individuals who are comfortable in a high-work high-reward environment, and who are enthusiastic for a dynamic and varied role. We are looking for people who fit well into our team and company culture, and who like to overcome challenges and drive the business forward. In exchange, we offer a competitive salary with performance related bonuses and stock options, alongside excellent career development opportunities in a fast-growing start-up with a chance to truly impact how cancer is treated.\r\n\r\nTo apply, please send your CV to info@ccg.ai", "one_liner": "CCG.ai empowers clinicians to make personalised treatment strategies…", "team_size": 25, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1495670432, "tags": [ "Genomics", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2017", "status": "Inactive", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United Kingdom", "Europe" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/cambridge-cancer-genomics", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2017/cambridge-cancer-genomics.json", "year_founded": 2015, "city": "Cambridge", "country": "GB", "linkedin_url": "", "x_url": "https://twitter.com/CCGenomics", "fb_url": null, "cb_url": "https://www.crunchbase.com/organization/cambridge-cancer-genomics", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/53b0518d38ef7cc187360951dee976ad809db1d9.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 195460, "full_name": "John Cassidy", "title": "Founder/CEO", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/john-w-cassidy", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/a09fdd7c7663987872a89785ed555287191901ac.jpg" }, { "user_id": 195868, "full_name": "Nirmesh Patel", "title": "Founder/Chief Scientific Officer", "founder_bio": "Scientist turned founder, trying to solve big problems and change the world!", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/nirmesh-patel/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/b95c957e6f36186997453224da349f1becbf6b67.jpg" }, { "user_id": 195908, "full_name": "Evaline Tsai", "title": "Founder/CPO", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/evaline-tsai-710b4386/", "x_url": "https://twitter.com/EvalineTsai", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/173c1510360021a6c88f401105de6a0a5c7df4aa.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1877, "name": "FidoCure®", "slug": "fidocure", "former_names": [ "The One Health Company", "FidoCure" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/bb9e634002d538d6dc6ede0e890087fb0447eb9b.png", "website": "https://www.fidocure.com/", "all_locations": "San Francisco, CA, USA; Palo Alto, CA, USA; Remote", "long_description": "Cancer is a genetic disease. We know this from decades of human and veterinary cancer research. Precision medicine and targeted therapies are successfully used to treat humans with cancer. At FidoCure®, we bring this approach to the world of veterinary medicine. \r\n\r\nFidoCure® empowers veterinarians to offer genetic sequencing and targeted therapies to treat dogs with cancer. We are committed to expanding the veterinary oncology toolbox for both diagnostics and therapeutics. \r\n\r\nOur veterinary partners have treated thousands of dogs over the past 30 years and work closely with the growing FidoCure® network of over 143 clinics and 180 forward-thinking veterinary oncologists throughout the US.\r\n\r\nTogether, we can combat canine cancer!", "one_liner": "FidoCure® is the leader in Precision Medicine for Canine Oncology.", "team_size": 14, "industry": "Healthcare", "subindustry": "Healthcare -> Healthcare Services", "launched_at": 1515099745, "tags": [ "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2018", "status": "Active", "industries": [ "Healthcare", "Healthcare Services" ], "regions": [ "United States of America", "America / Canada", "Remote", "Fully Remote" ], "stage": "Growth", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/fidocure", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2018/fidocure.json", "year_founded": null, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/the-one-health-company/", "x_url": "https://twitter.com/fidocure", "fb_url": "https://www.facebook.com/FidoCure/", "cb_url": "https://www.crunchbase.com/organization/the-one-health-company", "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/bb9e634002d538d6dc6ede0e890087fb0447eb9b.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 224682, "full_name": "christina lopes", "title": "Founder", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/christina-lopes-8679455/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/13ff42f8f331e256b550dbe1804de713ef08620e.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 1933, "name": "Clear Gene", "slug": "clear-gene", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/4c3988b74387b722e9f7364d78e224dbb7a5e2f7.png", "website": "https://cleargene.com", "all_locations": "San Francisco, CA, USA; San Carlos, CA, USA", "long_description": "", "one_liner": "Our tests help eradicate cancer by telling doctors whether they got…", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Diagnostics", "launched_at": 1616188654, "tags": [ "Healthcare", "Diagnostics", "Women's Health", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2018", "status": "Active", "industries": [ "Healthcare", "Diagnostics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/clear-gene", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2018/clear-gene.json", "year_founded": null, "city": "San Francisco", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/4c3988b74387b722e9f7364d78e224dbb7a5e2f7.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 107443, "full_name": "Brandon Steelman", "title": "Founder", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/brandonsteelman", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/dbfac65ce0120ecccc44ed6193892fdbf0d412c3.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 21852, "name": "Known Medicine", "slug": "known-medicine", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/64559b981b2b0426448690c07d39ec63246c6492.png", "website": "http://knownmed.com", "all_locations": "Salt Lake City, UT, USA", "long_description": "Known Medicine combines patient-specific 3D cell culture & AI to translate drugs to clinical success. We receive patient tumors, break them down, make thousands of micro-tumors, and then treat each with different drugs to determine which they will respond best to. \r\n", "one_liner": "Combining 3D cell culture & AI to translate drugs to clinical success", "team_size": 17, "industry": "Healthcare", "subindustry": "Healthcare", "launched_at": 1597169259, "tags": [ "AI-powered Drug Discovery", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2020", "status": "Acquired", "industries": [ "Healthcare" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/known-medicine", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2020/known-medicine.json", "year_founded": 2020, "city": "Salt Lake City", "country": "US", "linkedin_url": "https://www.linkedin.com/company/known-medicine/?viewAsMember=true", "x_url": "https://twitter.com/known_med", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/64559b981b2b0426448690c07d39ec63246c6492.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [], "jobs": [], "news": [ { "title": "Known Medicine is using machine learning to cure cancer", "url": "https://www.utahbusiness.com/known-medicine-is-using-machine-learning-to-cure-cancer/", "date": "Mar 28, 2023" } ], "launches": [] }, { "id": 23268, "name": "Zealth", "slug": "zealth", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/18c9dca3fe4fe586ecc86e321177f271f61a4ffb.png", "website": "https://zealth-ai.com/", "all_locations": "Bengaluru, KA, India; Remote", "long_description": "Zealth is building remote monitoring software to help hospitals provide automated continuous round-the-clock support to their cancer patients post-discharge. \r\n\r\nHospitals are overburdened with no resources to provide care to their chronic patients once they leave the hospital. For instance, in India, there are only 2200 oncologists for 1.38 billion people. Patients travel 100 miles waiting for hours to get few minutes with the doctors. They have no easy means to manage all the toxicities and symptoms they get once they are back home. This leads to 6X lower patient retention, 4X high emergency readmissions, and poor patient outcomes. \r\n\r\nZealth bridges this gap through its digital health intervention platform. ", "one_liner": "Software for remote monitoring of cancer patients", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Healthcare IT", "launched_at": 1615816186, "tags": [ "Health Tech", "Remote", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2021", "status": "Active", "industries": [ "Healthcare", "Healthcare IT" ], "regions": [ "India", "South Asia", "Remote", "Fully Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/zealth", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2021/zealth.json", "year_founded": 2020, "city": "Bengaluru", "country": "IN", "linkedin_url": "https://www.linkedin.com/company/zealth-ai/", "x_url": "", "fb_url": null, "cb_url": null, "github_url": "https://github.com/Zealth-AI", "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/18c9dca3fe4fe586ecc86e321177f271f61a4ffb.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 545382, "full_name": "Monika Mehta", "title": "Founder", "founder_bio": "Ph.D. Immunology, NUS, Singapore\nClinical Research Fellow, SingHealth, Singapore\nSenior Scientist, Chugai Pharma (Roche group), Singapore", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/monika-mehta-phd/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/27655fb4c751610bf490299b25bb972fd50fc4c3.jpg" }, { "user_id": 596881, "full_name": "Dheeraj Mundhra", "title": "Founder", "founder_bio": "Building Zealth - Software for remote monitoring of cancer patients.\nGraduated from IIT Kharagpur, Built multiple AI based products in finance and healthcare in the last 7 years.", "is_active": true, "linkedin_url": "https://linkedin.com/in/dmundhra", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/d604f8122db6ef74b9701ebb39a9c7722a2f6b86.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 24139, "name": "REPROSENT", "slug": "reprosent", "former_names": [ "Reprosent" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/70401adb14eed7e643c2ec631d7664fd02af2167.png", "website": "http://www.reprosent.com", "all_locations": "San Francisco, CA, USA; Los Gatos, CA, USA; Remote", "long_description": "REPROSENT is a patient-driven care system that harnesses patients' time to relieve overburdened medical teams. With an app that elevates the role of both patients and their loved ones, REPROSENT helps patients stay on track, capture previously untapped data about their lived experience, and receive timely triage that improves their health outcomes. By making crucial patient information actionable, REPROSENT enables doctors to focus their time on personalized treatment, transforming the way medical care is provided.", "one_liner": "Activating an overlooked force in medicine - the patient.", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare", "launched_at": 1627687580, "tags": [ "Biometrics", "Consumer Health Services", "Digital Health", "Healthcare", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2021", "status": "Active", "industries": [ "Healthcare" ], "regions": [ "United States of America", "America / Canada", "Remote", "Fully Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/reprosent", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2021/reprosent.json", "year_founded": 2020, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/reprosent/", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/70401adb14eed7e643c2ec631d7664fd02af2167.png", "app_video_url": null, "dday_video_url": null, "company_photos": [ "https://bookface-images.s3.us-west-2.amazonaws.com/attachments/4edbe7956473f8cbaa2e5298b698092981e1f8ca.png", "https://bookface-images.s3.us-west-2.amazonaws.com/attachments/818397e19ed54f77fe4060381b58fa3fab5841f9.png" ], "primary_partner": null, "founders": [ { "user_id": 613122, "full_name": "Aimee DeGolyer", "title": "Founder", "founder_bio": "Aimee DeGolyer has a history bringing new technology to market with a strong focus on understanding consumer needs and developing products to match. She has direct experience in oncology patient data through her time at Ciitizen, and created REPROSENT based on the experience she had losing her father in 2020 to an adverse reaction to his treatment. Additional previous startup experience includes: True Key, OnCue, and LightLogic.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/aimee-degolyer/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/50785be754be60a9bf11877b85225303555a0de0.jpg" }, { "user_id": 621317, "full_name": "Michael Sample", "title": "Founder", "founder_bio": "Over the years, I have helped build a variety of software solutions for a number of companies ranging from consumer startups to large enterprise companies. I'm the technical cofounder of Reprosent, a startup dedicated to improving patient outcomes with better data.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/mike-sample-1547521/", "x_url": null, "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/53cee06f447561c4ca1c6bf7d482543d20ab279a.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 25449, "name": "Alixia", "slug": "alixia", "former_names": [ "Guided Clarity" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/ff4093c59629c7638e73b36eb069911e0922c140.png", "website": "http://www.alixia.com", "all_locations": "San Francisco, CA, USA", "long_description": "Our compounds disrupt the metabolic and\r\ninflammatory triggers in both cancer and quasi-cancerous\r\ncells in the tumor microenvironment. By impacting multiple cell\r\ntypes, we are enabling effective, lasting cancer treatments.", "one_liner": "Targeting the Tumor Ecosystem to address cancer drug resistance.", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1648247483, "tags": [ "Biotech", "Therapeutics", "Drug discovery", "Oncology", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2022", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/alixia", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2022/alixia.json", "year_founded": 2022, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/alixia-therapeutics/", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/ff4093c59629c7638e73b36eb069911e0922c140.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 287726, "full_name": "Olof Mollstedt", "title": "Founder", "founder_bio": "", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/olof-mollstedt-95b4a1/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/56244742a9432a1e8ccb215b0bd26d98230bea8e.jpg" }, { "user_id": 293836, "full_name": "Helen Chen", "title": "Founder", "founder_bio": "Cancer & aging researcher | entrepreneur| mentor | ", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/helen-y-chen-7951641/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/dcfd0dfa105260c79bd854eac50dc82cda36da04.jpg" } ], "jobs": [], "news": [], "launches": [] }, { "id": 26427, "name": "Eugit Therapeutics", "slug": "eugit-therapeutics", "former_names": [ "EUGIT Tx", "EUGIT Therapeutics", "Eugit", "Eugit Therapeutics Inc" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/a88b74cc086730f852f068c605f2dcaa54b40a16.png", "website": "http://www.eugittx.com", "all_locations": "San Francisco, CA, USA; South San Francisco, CA, USA", "long_description": "Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years.\r\n\r\nCofounded by George Church (Harvard) and funded by Y Combinator (S22).", "one_liner": "Enabling Tissue Targeting of Therapies", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1656718658, "tags": [ "Cell Therapy", "Synthetic Biology", "Therapeutics", "Oncology", "Biotechnology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2022", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/eugit-therapeutics", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2022/eugit-therapeutics.json", "year_founded": 2022, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/eugit", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/a88b74cc086730f852f068c605f2dcaa54b40a16.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Jared Friedman", "url": "https://www.ycombinator.com/people/jared-friedman" }, "founders": [ { "user_id": 588526, "full_name": "Nizar Batada", "title": "Founder/CEO", "founder_bio": "Nizar is the co-founder and CEO at EUGIT, which he started with George Church in 2022. He is an expert in cancer research, genomics and bioinformatics and has published over 25 articles in peer-reviewed journals such as Nature and has obtained nationally competitive grants. Prior to EUGIT, he was a scientist at 23andMe and a tenure track lecturer at the University of Edinburgh, UK. Nizar grew up in Toronto and obtained his PhD in Biophysics from Stanford.", "is_active": true, "linkedin_url": "https://linkedin.com/in/nizar-batada", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/aa4ec5a091a22bc8ded999621c25385540ddb3cb.jpg" } ], "jobs": [], "news": [], "launches": [ { "id": 64275, "title": "EUGIT Therapeutics – Next generation T cell based cancer immunotherapy", "tagline": "Engineered gamma delta T-cells for off-the-shelf treatment of cancers", "body": "We are a therapeutics company that is developing immune cell based therapy for treatment of breast, ovarian and prostate cancers.\n\n**Problem**\n\nCancer remains an unsolved problem – it is expected that 1.8M new cancer cases and 0.6M cancer deaths will occur this year in the US (source CDC). Although development of immunotherapies such as checkpoint inhibitors and CAR-T cells have shown remarkable clinical success, they work for only a few cancer types. In particular, they do not work for some of the most common types of cancers in women (breast and ovarian) and men (prostate).\n\n**Solution**\n\nBuilding upon the discoveries of the founders, EUGIT Therapeutics is engineering cancer-fighting immune cells known as the gamma delta T cells which overcome the limitations of existing cancer immunotherapies.\n\n**How it works**\n\nWe take blood from healthy donors and isolate a specific type of immune cell called the gamma delta T cell and then endow them with cancer fighting activity via gene engineering. Our engineered T cells can be used off-the-shelf and ready for infusion into cancer patients.\n\n![uploaded image](/media/?type=post&id=64275&key=user_uploads/588526/a5ffcb03-a060-4080-9d9b-df2e92e6e72f)\n\n**Founders**\n\n[George Church](https://www.linkedin.com/in/george-church-2b86301/) (Co-Founder and Scientific Advisor): George is a Professor of Genetics at Harvard Medical School and leads Synthetic Biology at the Wyss Institute. His innovations have contributed to nearly all \"next generation\" DNA sequencing methods and companies (CGI-BGI, Life, Illumina, Nanopore). This plus his lab's work on chip-DNA-synthesis, gene editing and stem cell engineering resulted in founding additional application-based companies spanning fields of medical diagnostics ( Knome/PierianDx, Alacris, AbVitro/Juno, Genos, Veritas Genetics ) & synthetic biology / therapeutics ( Joule, Gen9, Editas, Egenesis, enEvolv, WarpDrive ). \n\n[Nizar Batada](https://www.linkedin.com/in/nizar-batada/) (Co-Founder and CEO): Nizar is a cancer biologist with over 20 years of experience working in genomics and cancer research. He did his PhD at Stanford and postdoc with George Church. Previously, he was a tenure track group leader at the University of Edinburgh where he directed a research lab that focused on cancer immunology. Before founding EUGIT therapeutics, he was a senior scientist at 23andMe’s Therapeutics division. The current work he is pursuing at EUGIT therapeutics is based on his discovery of a subtype of tumor infiltrating gamma delta T cells that are associated with good clinical outcomes in breast cancer. ", "url": "https://www.ycombinator.com/launches/Gih-eugit-therapeutics-next-generation-t-cell-based-cancer-immunotherapy", "votes": 20, "created_at": "2022-07-01T19:56:00.640Z" } ] }, { "id": 26734, "name": "Serinus Biosciences", "slug": "serinus-biosciences", "former_names": [ "Serinus" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/b6e7bac94ec8bfc7378ed11602bae7ea50215536.png", "website": "http://www.serinus.bio", "all_locations": "New York City, NY, USA; New York, NY, USA", "long_description": "Serinus Biosciences is tackling one of the toughest problems in cancer treatment: creating combination therapies to override treatment resistance. We leverage cutting edge technology to design a fully explainable AI platform primed with decades of system biology knowledge. Uniquely powered for biological inference, our AI engine uncovers how cancer cells evolve treatment resistance and identifies molecules to overcome resistance escape routes. We design combinations that are safer, more effective, and can get to patients quickly. Founded by MIT PhDs and supported by a scientific advisory board of top academics from the Broad Institute, Dana-Farber, and UCSD, Serinus is powered by Y Combinator and other top investors to revolutionize precision medicine.", "one_liner": "Combinations therapy by rational design", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1656454958, "tags": [ "Biotech", "Therapeutics", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2022", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/serinus-biosciences", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2022/serinus-biosciences.json", "year_founded": 2022, "city": "New York City", "country": "US", "linkedin_url": "https://www.linkedin.com/company/serinus-biosciences", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/b6e7bac94ec8bfc7378ed11602bae7ea50215536.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 995566, "full_name": "Adam Yaari", "title": "Founder/CEO", "founder_bio": "Prior to founding Serinus, Adam gained over 10 years of entrepreneurship experience including a Microsoft R&D Fellowship and Flagship Pioneering Ideation Fellowship. Adam is passionate about developing advanced AI models for biological research that will bring medicine to scale.\nAdam received his PhD and MS in computer science from MIT, MSc in computer science and mathematics from the Weizmann Institute of Science, and dual major BSc in computer science and neuroscience from Bar-Ilan University.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/adam-yaari-b0192ab4/", "x_url": "https://twitter.com/adamyaari", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/be559be7ab070663acd06da510435c67603327ef.jpg" }, { "user_id": 1018692, "full_name": "Maxwell Sherman", "title": "Founder/CTO", "founder_bio": "After five years as a paramedic, Max left clinical medicine to develop new treatments for the millions of patients without access to effective medications. He studied applied math and biology at Brown University, statistics at Cambridge University, and is completing his PhD in computational biology at MIT. His research has appeared in prestigious journals including Science, Nature Biotechnology, and Nature Neuroscience and has been recognized with national and international awards.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/maxwellsh/", "x_url": "https://twitter.com/m_a_sherman", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/55ef582cd6624db1323147e32a73d8b92ba0f26c.jpg" } ], "jobs": [], "news": [], "launches": [ { "id": 65562, "title": "Serinus Biosciences: Killing cancer with its own genetics 💪🏽", "tagline": "We develop drugs effective against multiple types of cancer... and we do it really fast! 🏃🏽", "body": "We're **Adam** and **Max**, the founders of **Serinus Biosciences** 💊💻🤓\n\nAt Serinus, we develop drugs that are effective against **multiple types of cancer**, and because cancer patients need solutions now, we do it in **months instead of years!**\n\n### **_Cancer: an insidious disease with insidious economics_** 💰💰💰\n\nCurrently, **more than 80% of cancer patients** are not eligible for targeted cancer therapies - the most efficient and least toxic cancer treatments. _Why?_ Because the proteins driving cancer in one patient are often different than those driving cancer in another patient.\n\nHere's where the economics comes in. The cost of bringing a new cancer drug to market is currently **>$2.5 BILLION**. Developing a drug against a protein that only causes cancer in a small number of patients each year is just not economically viable with traditional drug development.\n\n### **_The Serinus Strategy_** 💡\n\nWhile building AI tools to understand the causes of cancer during our PhDs at MIT, we had a realization: all the different cancer-causing proteins disrupt the same cellular systems. **We shut down these shared dysfunctional systems.**\n\n_How?_ We look for the support proteins that keep the system functioning. Think about a telephone system ☎️ If you want to bring it down, you should find the small number of relay stations that route messages across the network instead of hitting the individual phones. **We find the relay stations of cancer cells and bring them dow**n ☠️☠️☠️\n\nSince cancer systems are widely shared across patients, the relays that support those systems are widely shared across patients. Our current pipeline **could help more than 100K PATIENTS PER-YEAR!**\n\n### **_The knowledge (and stubbornness) to get it done_** 🤓 😎\n\nWe met on the very first day of our PhDs at MIT. It was a cancer-fighting match made in heaven. Adam comes from an AI/ML background, Max comes from a biology and statistics background, having given up his place in medical school so he could develop new treatments for patients in need by merging biology, mathematics, and computer science.\n\nOh, and did we mention that Adam is a former Navy SEALs commander and Max spent five years as a paramedic.\n\n**_How can you help?_**\n\nOur platform is churning out way more ways to kill cancer than we can pursue ourselves. If you or someone you know works at another therapeutics company that might be interested in co-developing a drug with us, give us a shout on [founders@serinus.bio](mailto:founders@serinus.bio)", "url": "https://www.ycombinator.com/launches/H3S-serinus-biosciences-killing-cancer-with-its-own-genetics", "votes": 39, "created_at": "2022-08-23T01:28:16.522Z" } ] }, { "id": 27263, "name": "Guardian Bio", "slug": "guardian-bio", "former_names": [ "GuardianBio" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/686bc0e4b74ba3953559c1bb8515351010e84b61.png", "website": "http://www.guardian-bio.com", "all_locations": "Boston, MA, USA", "long_description": "Your immune system is your body’s best weapon and defense against cancer. It is only when it is overcome that cancer develops into full blown disease. Dendritic cells sit at the helm of the immune system, directing and dictating immune responses. Data has shown dendritic cells are often dysfunctional in cancer patients, and that this dysfunction is a bottleneck for other therapies. \r\n\r\nGuardian Bio’s approach is focused on creating a dendritic cell-based product which drives anti-tumor activity through activating the killers of the immune system AND training them against multiple cancer targets. We take stem cells from cancer patients, turn them into specific therapeutic dendritic cells specially trained against that patient’s tumor, and re-introduce them back into the body. \r\n\r\nOur therapeutic dendritic cells revitalize the killers of the immune system and give them the kickstart they need to fight - and win - against cancer.", "one_liner": "Dendritic cell-based platform for cancer therapy ", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1657134176, "tags": [ "Biotech", "Healthcare", "Therapeutics", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2022", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/guardian-bio", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2022/guardian-bio.json", "year_founded": 2022, "city": "Boston", "country": "US", "linkedin_url": "https://www.linkedin.com/company/guardian-bio", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/686bc0e4b74ba3953559c1bb8515351010e84b61.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 1010650, "full_name": "Ananya Zutshi", "title": "Founder", "founder_bio": "Ananya is Co-Founder and CEO of Guardian Bio, a company which controls immunity using dendritic cell-based therapies. \n\nShe has a Bachelors in Science in Engineering from Duke and Masters in Engineering and MBA from Harvard. Her experiences span across the pharma/biotech industry in operations, engineering, project management, and early stage investing. She is passionate about delivering better therapies for patients and diversity, equity, and inclusion. ", "is_active": true, "linkedin_url": "http://linkedin.com/in/ananya-zutshi/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/5da6cf610555e8dcbaf0a7a21c5130928b164133.jpg" }, { "user_id": 1080360, "full_name": "Ricky Barrett", "title": "Founder", "founder_bio": "Co-founder and CSO at Guardian Bio.\n\nRicky started his career as a marine biologist and research diver at FAU with a focus on marine natural products and drug discovery. \n\nHe pursued a PhD at UCF, focused on immunology followed by a postdoc in cancer immunology and tumor microenvironment at the University of Pennsylvania.\n\nRicky is a prolific science communicator creating educational science content for an audience of over a quarter million followers across various social media platforms.", "is_active": true, "linkedin_url": "http://www.linkedin.com/in/rickbarrett21/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/d88e6393dfe01aade28a018e01a7447dab3b88e4.jpg" } ], "jobs": [], "news": [], "launches": [ { "id": 65615, "title": "Guardian Bio - Control Immunity with Dendritic Cells", "tagline": "We make dendritic cells from a patients own stem cells and program them to cure diseases, starting with cancer.", "body": "# tl;dr\n\nYour immune system keeps you healthy. If it loses control, diseases like cancer, chronic infections, and autoimmunity can develop. We created a platform that enables us to produce a master regulator of the immune system (the dendritic cell) from patient stem cells. We program these cells so that they can make corrections to dysfunctional immune systems and bring disease back under control. We’re starting with cancer.\n\n# Team\n\nPrior to starting Guardian Bio, Ananya…\n\n* Was a Blavatnik Fellow at Harvard Business School, a fellowship fostering life science entrepreneurship \n* Worked across Operations, Engineering, and Project Management in the manufacturing and development side of the pharma/biotech industry\n* Received dual Masters in Engineering Sciences and MBA from Havard, where she was a Kaplan Fellow, and graduated with honors from Duke with a degree in Biomedical Engineering\n\nPrior to starting Guardian Bio, Ricky…\n\n* Was a Postdoctoral Fellow at University of Pennsylvania - tumor microenvironment, tumor immunity, and cell therapy\n* Co-Founded the Philadelphia chapter of Nucleate, a free and collaborative trainee-led organization that facilitates the formation of pioneering life sciences companies\n* Earned a PhD in Biomedical Sciences - Immunology at University of Central Florida\n* Worked as a marine biologist and scientific diver at Florida Atlantic University\n* And continues to create science communication content for social media platforms, reaching an audience of over a quarter million followers across TikTok and Instagram\n\n# The Problem\n\nThe overall problem is that the immune system unfortunately can’t always maintain control over disease. Cancer specifically actively suppresses the immune system. It has to. If the immune system maintains control, it will kill the cancer and disease will not develop. \n\nOne of the immune cell types often suppressed by cancer are dendritic cells, which sit at the helm of the immune system. Dendritic cells (DCs) direct and dictate immune responses. DCs are often deficient or dysfunctional in cancer patients, creating severe limitations in the body’s ability to fight off cancer, even when treatments like chemo and immunotherapy are applied.\n\n# The Solution\n\nWe take stem cells from cancer patients, turn them into dendritic cells, program them against that patient’s tumor, and re-introduce them back into the body. This stimulates a diverse yet targeted and robust immune response against the cancer. \n\n# The Platform\n\nOur dendritic cell-based platform can be adapted to a variety of diseases. When we train DCs against different targets, our therapy can reignite immune responses against chronic infectious diseases or suppress immune cells triggering autoimmunity.\n\nOur dendritic cell-based therapy is synergistic with many other immunotherapies including checkpoint inhibitors, peptide and mRNA-based cancer vaccines, oncolytic viruses, etc, potentially extending the reach of these therapies to patients who would not have responded before.\n\n![](https://lh3.googleusercontent.com/Fog7y2f3-PsbDww_4qw_LbLzzzM_3yXUEMVPMps50vCfN5dnHauQFTn72dLW2hd1RjKghsjpl8HwpSrJ_zMOe-QneWuKm_BLkumbU-01HqsRlLddaJ8713teujTfrYSRd0y9lsxxqffoBgvUwzGsXg)\n\n", "url": "https://www.ycombinator.com/launches/H4J-guardian-bio-control-immunity-with-dendritic-cells", "votes": 21, "created_at": "2022-08-25T13:47:55.461Z" } ] }, { "id": 28158, "name": "Adventris Pharmaceuticals", "slug": "adventris-pharmaceuticals", "former_names": [ "Elimivax" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/5c8bb0a987c29df94410bb9cc6ab7db9eb0d6478.png", "website": "https://adventris.com", "all_locations": "Baltimore, MD, USA", "long_description": "Adventris makes cancer vaccines. Our platform solves the problem of targeting poorly immunogenic oncogenes. Our first \"off-the-shelf\" vaccine targets KRAS, the most common cancer oncogene. In the long run, we envision a world where every adult receives our pan-cancer vaccines annually – preventing the majority of cancer deaths.\r\n\r\nIf you are interested in learning more about our approach to treat and prevent cancer, please reach out to us at contact@adventris.com", "one_liner": "Adventris makes cancer vaccines", "team_size": 7, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1675190671, "tags": [ "Biotech", "Healthcare", "Therapeutics", "Drug discovery", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2023", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/adventris-pharmaceuticals", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2023/adventris-pharmaceuticals.json", "year_founded": 2022, "city": "Baltimore", "country": "US", "linkedin_url": "", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/5c8bb0a987c29df94410bb9cc6ab7db9eb0d6478.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Tom Blomfield", "url": "https://www.ycombinator.com/people/tom-blomfield" }, "founders": [ { "user_id": 1145057, "full_name": "Jen Herbach", "title": "Founder", "founder_bio": "Jen Herbach is the CEO of Adventris Pharmaceuticals. She has more than a decade of biotech industry experience bringing novel oncology drugs to market, across companies including Onyx/Amgen, InterMune/Genentech, Exelixis, and Amunix. She holds an MBA from Harvard Business School and a Masters from the University of Cambridge.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/jennylesser/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/a4adf9402b75db976cbf8cf9bc9daa3538d621d2.jpg" }, { "user_id": 1157162, "full_name": "William Collis", "title": "Founder", "founder_bio": "William Collis is a serial entrepreneur with multiple exits, most recently the data platform Genji. His research has been published in Harvard Business review and featured as a TED talk with over 1.5M views. He holds an MBA from Harvard Business School where he was named a Baker Scholar. He is lifelong friends with his co-founders Jen Herbach and Mark Yarchoan, since meeting as roommates at Amherst College.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/william-collis-145a2511/", "x_url": "https://twitter.com/William_Collis", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/b5c77e81b24d9b47c77c2c401669aded99074923.jpg" }, { "user_id": 1163176, "full_name": "Mark Yarchoan", "title": "Founder", "founder_bio": "Mark Yarchoan, M.D, is an Associate Professor of Medical Oncology at Johns Hopkins. Dr. Yarchoan runs an NCI-funded laboratory focused on developing novel immunotherapies, with a focus on cancer vaccines. He has led multiple international clinical trials of immunotherapy agents including neoantigen-targeted cancer vaccines. Dr. Yarchoan has received multiple honors, including the ASCO Young Investigator Award and the ASCO Career Development Award.", "is_active": true, "linkedin_url": "", "x_url": "https://twitter.com/markyarchoan", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/57e4f209a83f48b812a625fa97dad9138e582500.jpg" } ], "jobs": [], "news": [], "launches": [ { "id": 68893, "title": "Adventris Pharmaceuticals - We make cancer vaccines!", "tagline": "By teaching our body’s immune system to recognize and kill the mutations that cause cancer we can eliminate the majority of all cancer deaths.", "body": "**ABOUT ADVENTRIS**\n\nAdventris makes cancer vaccines. By teaching our body’s immune system to recognize and kill the mutations that cause cancer, we can eliminate the majority of all cancer deaths.\n\n**OUR SCIENCE**\n\nA normal cell turns into cancer when it develops a mutation that makes it grow aggressively. Surprisingly, a small number of these mutations account for the vast majority of cancer deaths. The immune system usually doesn’t recognize these mutations, but our technology platform enables us to train the immune system to recognize and attack these cancers. Our first product is a vaccine for the treatment of lung cancer that targets the KRAS mutation, the most common mutation in cancer, accounting for about 25-30% of all cancer deaths. In the long run, we envision a world where every adult receives our vaccines annually – preventing the majority of cancer deaths.\n\n**OUR TEAM** \n\nOur team includes some of the leading cancer vaccine experts in the world including: our Chief Medical Officer, Dr. Mark Yarchoan (principal investigator of multiple international cancer vaccine clinical trials) and our Scientific Co-Founder, Dr. Liz Jaffee. Our team is led by our Chief Executive Officer, Jen Herbach, who has more than a decade of biotech industry experience including with Amunix (the second largest oncology pre-clinical stage acquisition).\n\n![uploaded image](/media/?type=post&id=68893&key=user_uploads/1145057/259fde86-331d-4477-83f2-f7f6e5461adf)\n\n**INTERESTED IN LEARNING MORE** \n\nIf you are interested in learning more about our approach to treat and prevent cancer, please reach out to us at [contact@adventrispharma.com](mailto:contact@adventrispharma.com)", "url": "https://www.ycombinator.com/launches/HvB-adventris-pharmaceuticals-we-make-cancer-vaccines", "votes": 61, "created_at": "2023-01-31T19:18:22.720Z" } ] }, { "id": 28205, "name": "Modulari-T", "slug": "modulari-t", "former_names": [ "Modulari-T Biosciences" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/cdfde836f1d168c7ec0299ab6b4daf90d112f929.png", "website": "https://modularit.bio", "all_locations": "Montreal, QC, Canada; San Francisco, CA, USA", "long_description": "Cell and gene therapy promises to one day cure any disease; Modulari-T’s Platform produces the tools to fulfill that promise.\r\n\r\nModulari-T has designed a new family of synthetic genes that can reprogram cells to better sense their environment and modify their behavior accordingly. This can be used to engineer immune cells to efficiently recognize and kill cancer cells or to create stem cells able to regenerate any tissue.\r\n\r\nModulari-T looks to expand its technology to reach every area of cell therapy and become the platform of reference for cell engineering.", "one_liner": "We teach your immune system to attack and cure cancer", "team_size": 4, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1675126815, "tags": [ "Gene Therapy", "Cell Therapy", "Synthetic Biology", "Biotech", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2023", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "Canada", "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/modulari-t", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2023/modulari-t.json", "year_founded": 2021, "city": "Montreal", "country": "CA", "linkedin_url": "https://www.linkedin.com/company/modulari-t-bio/", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/cdfde836f1d168c7ec0299ab6b4daf90d112f929.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 1049972, "full_name": "David White", "title": "Founder", "founder_bio": "David is the CEO and cofounder of Modulari-T. His expertise spans multiple areas and he is driven by a passion for pushing the boundaries of technology.\n\nDuring his PhD he discovered how protein receptors form complex structures that allow them to alter cells’ behavior. He then took this knowledge and the novel technology that was developed to build Modulari-T.\n\nWhen he’s not thinking up a new way to engineer cells he can be spotted biking or running up a mountain.", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/david-white-modulari-t/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/02ce0c5af1e07f18b7b09b99212309d6f1df723e.jpg" }, { "user_id": 1161771, "full_name": "Stephanie Mok", "title": "Founder", "founder_bio": "Co-founder and COO at Modulari-T. PhD in chemical engineering. Technical background in synthetic biology, advanced 3D cell culture systems, and biomaterials in the context of the cellular cancer microenvironment. Fascinated by the innovations cell-based therapies, food products, and the scale up of their manufacturing. Gave the unconference talk \"Lessons learned and mistakes made growing the world's hottest peppers\".", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/stephmok/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/7e84b9438e87a1adf29d92d2525871a030ab8753.jpg" } ], "jobs": [], "news": [], "launches": [ { "id": 68886, "title": "Modulari-T 🧬 Unleash the full power of the immune system", "tagline": "We teach your immune system to attack and cure cancer.", "body": "# Modulari-T AWAY!\n\nHi YC, this is [@David](https://www.linkedin.com/in/david-white-modulari-t/) and [@Stephanie](https://www.linkedin.com/in/stephmok/) from [@Modulari-T](https://www.linkedin.com/company/modulari-t-bio/) launching!\n\n### **WHAT WE DO**\n\nModulari-T is a cell therapy company that can teach your immune system to attack and cure cancer.\n\n \n\nWe are a dynamic group of scientists bringing together protein engineering, synthetic biology, and immunology to create the world’s most powerful cell programming platform.\n\n \n\nBy introducing our optimized gene sequences inside immune cells, we can create treatments that are 2x potent as chemotherapy, but that avoids 90% of harmful side-effects.\n\n \n\nToday, cell therapy has a high failure rate and is difficult to produce, leaving 20M patients without hope. Modulari-T has the technology to fix this, bring hope to cancer patients, and supercharge the cell therapy market to grow beyond $50B by the end of the decade.\n\n \n\n### **HOW YOU CAN HELP**\n\nConnect us with people in the ecosystem! Do you know anyone working in cell therapy or oncology? We want to talk to them, to know about their pain points - academic, biotech/pharma or physicians.\n\n[We are hiring!](https://modulari-t.breezy.hr/) Are you a synthetic biologist or immunologist? Ready to join a new adventure? Become part of the Modulari-T squad (Mod Squad!) in beautiful Montreal!\n\n### **THE SCIENCE**:\n\nWe have built a platform to produce a new type of receptor, the Modular Actuation Receptor Complex or MARC, that mimics the modular architecture of immune receptors. These receptors can be used to reprogram immune cells to recognize cancer antigens and direct an immune response against tumor cells. Compared to CAR-T cells, MARCs have twice the tumor clearing power and avoid causing immune exhaustion to ensure a long lasting response.\n\n![](https://lh6.googleusercontent.com/ItKO7egaIuynMGKcNjoT2YMqkANZ6E6oNxe5RyIisJ47KOaWhchZU9NpFHXfqkGu_EIB6--huJ4KOnT_5IqHMQut2czid5T8krpDXcZ3iSYTSEL9y2tyAg2IfOYSLic_Uaiz7dOJbcH6dELlc-MPEA)\n\nThe MARC’s unique architecture allows us to link any extracellular cue with the required signalling outputs across different pathways to achieve therapeutic success.\n\n![uploaded image](/media/?type=post&id=68886&key=user_uploads/1161771/abbed6b1-a7be-43e4-821c-8daa69fff47a)\n\nOncology is only the first step; the MARC platform is applicable to autoimmunity, neurology, regenerative medicine and more!\n\n### **HOW WE CAN HELP YOU**\n\nAre you a Cell Therapy company? Let us show you how Modulari-T’s MARC platform can help your development. Our platform can do anything but we can’t do everything alone. That’s why we want to partner with you and bring hope to as many patients as we can.\n\n### Thank you!\n\n![uploaded image](/media/?type=post&id=68886&key=user_uploads/1161771/773beb5d-3dbb-4905-8b5e-c5e453a33517)\n\n", "url": "https://www.ycombinator.com/launches/Hv4-modulari-t-unleash-the-full-power-of-the-immune-system", "votes": 863, "created_at": "2023-01-31T18:07:52.539Z" } ] }, { "id": 29305, "name": "SynsoryBio", "slug": "synsorybio", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/e2b7538a15335c79e864ff7431e761c3feca0797.png", "website": "https://www.synsorybio.com/", "all_locations": "Boston, MA, USA", "long_description": "SynsoryBio is creating next generation, protein therapeutics that sense where they are in the body and only activate at diseased tissue. This technology platform has the potential to expand the therapeutic window of highly potent drugs and apply to many diseases such as cancer and autoimmune disorders.", "one_liner": "\"If-then\" conditional logic for protein drugs", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1707422039, "tags": [ "Synthetic Biology", "Biotech", "Therapeutics", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2024", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/synsorybio", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2024/synsorybio.json", "year_founded": 2023, "city": "Boston", "country": "US", "linkedin_url": "https://www.linkedin.com/company/synsorybio/", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/e2b7538a15335c79e864ff7431e761c3feca0797.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": null, "founders": [ { "user_id": 1336498, "full_name": "Elliot Tague", "title": "Founder", "founder_bio": "I am a PhD and inventor in the fields of synthetic biology and protein engineering. I got my PhD from Boston University, spent time as a visiting graduate student in George Church's lab at Harvard, and worked in various biotech startups", "is_active": true, "linkedin_url": "https://linkedin.com/in/elliot-tague", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/862fd5995470be60ee9592f62023e7535f5ba456.jpg" }, { "user_id": 1609260, "full_name": "Nathan Tague", "title": "Founder", "founder_bio": "I’m a co-founder of SynsoryBio, where we are creating therapeutics that sense-and-respond to disease. I have a background in synthetic biology and protein engineering with a PhD in Biomedical Engineering.", "is_active": true, "linkedin_url": "https://linkedin.com/in/nathan-tague-533019198", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/64f7893e259c04691fa3d527943ce549ccc78d95.jpg" } ], "jobs": [], "news": [], "launches": [ { "id": 78311, "title": "SynsoryBio: Therapeutics that sense-and-respond to disease", "tagline": "Our immune system acts locally to combat disease, why don’t our medicines?", "body": "**TL;DR**\n\nAt SynsoryBio, we engineer \"_if-then_\" conditional logic into protein medicines, meaning only _if_ the protein drug senses a disease marker, _then_ it turns on. We are applying this technology to clinically tested, but highly toxic cancer immunotherapies to make them safer and more effective. \n\n**Who we are/Team:**\n\nSynsoryBio was founded by brother scientists, [Elliot](https://www.linkedin.com/in/elliot-tague/) and [Nathan](https://www.linkedin.com/in/nathan-tague-533019198/), who both hold PhDs in biomedical engineering. The founders gained expertise in synthetic biology at Boston University, Harvard Medical School, and industrial biotech, where they authored numerous high-impact journal publications and are inventors on several patent filings. SynsoryBio harnesses this expertise to create next-generation therapeutics that understand where they are in the body and only act at the site of disease. \n\n![uploaded image](/media/?type=post&id=78311&key=user_uploads/1336498/724512c9-7cee-4c6b-ba4f-ea2550ef57d9)\n\n**The Problem:**\n\nThe most potent therapeutics suffer from safety issues and dose limitations, impeding their development and overall efficacy. This isn’t surprising because most therapeutics are delivered systemically and are active throughout the body even though the underlying disease is localized to a certain tissue. For example, immunotherapies to treat cancer show great promise but usually exhibit dose limitations, especially in combination, which prevents the development of potent immune stimulators and/or mitigates clinical efficacy.\n\n \n\n**The Synsory Solution:**\n\nWe are developing next-generation protein therapeutics that have synthetic sensing functions so that they know where they are in the body and only act at disease tissue. Our approach is highly flexible, allowing us to design protein therapeutics that conditionally activate upon sensing virtually any specified biomolecule.\n\n![uploaded image](/media/?type=post&id=78311&key=user_uploads/1336498/66febfad-2442-4c03-be04-050f4149b862)\n\n**Our ask:**\n\n\\-If you know any immunologists or oncologists, we would love to connect with them!\n\n\\-Interested in partnering? Please reach out!\n\n Connect with us, info@synsorybio.com", "url": "https://www.ycombinator.com/launches/KN5-synsorybio-therapeutics-that-sense-and-respond-to-disease", "votes": 31, "created_at": "2024-02-09T15:34:58.143Z" } ] }, { "id": 29429, "name": "Velorum Therapeutics", "slug": "velorum-therapeutics", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/f201fcf7f4408f2acdedabe7f9bef2baabec8369.png", "website": "https://www.velorumtx.com/", "all_locations": "San Francisco, CA, USA", "long_description": "Velorum Therapeutics is developing breakthrough medicines by unlocking the biology of heme.", "one_liner": "Breakthrough medicines unlocking the biology of heme", "team_size": 5, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1706719304, "tags": [ "Biotech", "Healthcare", "Therapeutics", "Drug discovery", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2024", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/velorum-therapeutics", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2024/velorum-therapeutics.json", "year_founded": 2023, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/velorumtx/", "x_url": "https://twitter.com/velorumtx", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/f201fcf7f4408f2acdedabe7f9bef2baabec8369.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Jared Friedman", "url": "https://www.ycombinator.com/people/jared-friedman" }, "founders": [ { "user_id": 1650103, "full_name": "Pouya Modareszadeh", "title": "Founder/CEO", "founder_bio": "Co-Founder & CEO @ Velorum Therapeutics. Building new medicines.", "is_active": true, "linkedin_url": "https://linkedin.com/in/pouya-modareszadeh", "x_url": "https://twitter.com/pouyamodares", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/58cc892e4fc1058532de364a1d07fab281272f8a.jpg" }, { "user_id": 1647572, "full_name": "Parsa Modareszadeh", "title": "Founder/President", "founder_bio": "Co-Founder and President @ Velorum Therapeutics. Goldwater Scholar. Working to create breakthrough medicines for devastating diseases. ", "is_active": true, "linkedin_url": "https://linkedin.com/in/parsa-modareszadeh", "x_url": "https://twitter.com/parsamodares", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/37709050b73a0ef7baf2d4d22bf250ec935ea51e.jpg" } ], "jobs": [], "news": [], "launches": [ { "id": 78069, "title": "Velorum Therapeutics: Powerful cancer drugs that starve tumors", "tagline": "We're developing a new class of cancer drugs that starve tumors by hijacking cancer metabolism.", "body": "### **ABOUT VELORUM**\n\n[**Velorum Therapeutics**](https://www.velorumtx.com/) **is developing a new class of cancer drugs that starve tumors by hijacking cancer metabolism. We have shown our drugs work in mice and plan to begin human clinical trials next year, starting with the #1 cancer killer – lung cancer.**\n\n### **OUR SCIENCE**\n\n**We’ve discovered that cancers are addicted to a molecule called ‘heme’.** Heme, which is well-known as the central component of ‘hemoglobin’, is used by the mitochondria to make energy. Cancers ‘steal’ free-floating heme from the blood to fuel their rapid growth. **Our patented drugs starve cancer by removing this heme that cancer cells need, but normal cells don’t.** We’ve shown in animals that our drugs are highly effective for multiple cancers, without affecting healthy cells, even at the highest doses. Also, by starving tumors, we make them weaker and more susceptible to existing cancer treatments, like radiation, chemo, and immunotherapies.\n\nThe body has a natural system to clean up this free-floating heme, but it gets overwhelmed by cancer. **Our drugs essentially amplify the body’s natural heme removal system.** We let nature do most of the work – our drugs are built from proteins that have evolved over millennia to be perfect at capturing heme. Importantly, heme is the exact same molecule across all mammals, meaning the results we see in animals have a higher chance of translating to humans.\n\nWe’re starting with lung cancer, with a lead drug advancing to first-in-human trials next year. **Because multiple types of cancers have this same vulnerability, our lead drug could potentially be used for lots of cancer types and become a standard-of-care treatment.**\n\n### **OUR TEAM**\n\n[Parsa](https://linkedin.com/in/parsa-modareszadeh) and [Pouya](https://linkedin.com/in/pouya-modareszadeh) are twin brothers and scientists who spent their entire adult lives studying how cancers make energy. They worked together on this breakthrough science over the past 5 years, helping develop this promising new class of cancer drugs. They founded Velorum to advance this breakthrough to patients, surrounding themselves with a team of world-class drug developers, scientists, and clinicians.\n\n![uploaded image](/media/?type=post&id=78069&key=user_uploads/1647572/3e39d62c-27d4-4f86-8e4b-94e9bc70772e)\n\n### **CONTACT US**\n\nTo learn more about our science or support us on our mission, please reach out at [info@velorumtx.com](mailto:info@velorumtx.com)", "url": "https://www.ycombinator.com/launches/KJB-velorum-therapeutics-powerful-cancer-drugs-that-starve-tumors", "votes": 30, "created_at": "2024-02-01T18:56:30.462Z" } ] }, { "id": 29470, "name": "Eris Biotech", "slug": "eris-biotech", "former_names": [], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/b16bbab6bd8003573ebc3410a08531b90c3427fd.png", "website": "http://www.erisbio.com", "all_locations": "Salt Lake City, UT, USA", "long_description": "We are developing cancer therapeutics using small molecules that inhibit immune suppression. Our drugs engage the immune system to aggressively fight tumors. Our therapeutic portfolio addresses a range of solid tumors, starting with mesothelioma. ", "one_liner": "Our drugs engage the immune system to fight tumors", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1706246904, "tags": [ "Biotech", "Therapeutics", "Drug discovery", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2024", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/eris-biotech", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2024/eris-biotech.json", "year_founded": 2023, "city": "Salt Lake City", "country": "US", "linkedin_url": "https://www.linkedin.com/company/eris-biotech/about/", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/b16bbab6bd8003573ebc3410a08531b90c3427fd.png", "app_video_url": null, "dday_video_url": null, "company_photos": [ "https://bookface-images.s3.us-west-2.amazonaws.com/attachments/ee9d713077a9b1c11574e3f90def5175741b1175.png" ], "primary_partner": null, "founders": [ { "user_id": 1579332, "full_name": "Evita Weagel", "title": "Founder/CEO", "founder_bio": "PhD in microbiology and molecular biology with an emphasis in cancer immunology, working on developing drugs that reawaken the immune system to fight cancer. First-generation immigrant from Peru. Mom of two boys. ", "is_active": true, "linkedin_url": "https://linkedin.com/in/evita-weagel-ph-d-62b19737", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/34d1d8b3169bd0d47404851e7b84984278e9283b.jpg" }, { "user_id": 1593818, "full_name": "Rachel Garlick", "title": "Founder", "founder_bio": "PhD in Immunology from Dartmouth College. Engineered many novel cancer immunotherapies. We build cancer drugs that reawaken the immune system to fight cancer for you. No tox, no side effects, and most importantly -- no cancer. ", "is_active": true, "linkedin_url": "https://linkedin.com/in/rachel-brog-garlick", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/aef2fc87092832c891b54c739d321fcad28adcd0.jpg" } ], "jobs": [], "news": [], "launches": [ { "id": 78251, "title": "Eris Biotech - Developing drugs that reawaken the immune system to kill cancer", "tagline": "Tumors turn OFF the immune system. Our drugs turn the immune system ON to kill cancer.", "body": "**About us**\n\nHello 👋 We’re [Evita](https://www.linkedin.com/in/evita-weagel/) and [Rachel](https://www.linkedin.com/in/rachel-brog-garlick/), co-founders of [Eris Biotech](https://www.linkedin.com/company/eris-biotech). We met working at the same lab at BYU when Evita was a Ph.D. student and Rachel was an undergrad. We collaborated on a peer-reviewed paper and conference presentations, and we’ve been friends since! Rachel went on to Dartmouth for her Ph.D. and later worked at a startup developing cell therapies. Evita went on for a postdoc and a career in drug development in big pharma. Rachel has developed multiple novel therapies for patients and Evita has brought numerous drugs to the clinic. We’re excited to bring our expertise together to build a first-in-class treatment that follows our mission to aggressively fights cancer, but also improve the patient experience.\n\n![uploaded image](/media/?type=post&id=78251&key=user_uploads/1579332/86e96bb5-bf3c-4acc-9041-1efbe0d836a0)\n\n**Our Backstory**\n\nEvita, working in drug development, saw promising cancer drugs fail because they were simply too toxic. Rachel, in cell therapy, saw the same problem as treatments that worked in principle caused too much collateral damage. Both realized that the real issue was not just the drugs themselves but the way most cancer treatments rely on toxic approaches that also wipe out our best weapon against cancer, the immune system. Tumor immune evasion is one of cancer’s greatest strengths, yet few were tackling it head-on. We founded Eris Biotech to change that and to develop therapies that stop tumors from hiding and reawaken the immune system.\n\n**The Problem**\n\nOne of cancer’s greatest weapons is its ability to hide from the immune system. Tumors release billions of **tiny vesicles** that contain “don’t attack me signals” and shut down the immune system, blinding it to their presence. This immune evasion lets cancer spread unchecked while most current treatments, such as chemotherapy, radiation, and even some immunotherapies, further weaken the body’s natural defenses.\n\n**Our Solution**\n\nEris Biotech develops small-molecule drugs that prevent tumors from forming and releasing immune-suppressing **tiny vesicles**. By stopping this process, we remove cancer’s disguise, restore immune surveillance, and give the body’s natural defenses the upper hand. Essentially, our drug doesn’t kill cancer directly like toxic chemotherapies – instead, our drug awakens the immune system to fight cancer for you. This approach targets one of cancer’s most powerful survival strategies while avoiding the high toxicity of traditional treatments. We’re starting by targeting mesothelioma, a cancer of the lung lining, with a 5-year survival rate under 13 percent.\n\n**Contact us**\n\nIf you want to learn more about our science and mission, you can reach us at [**founders@erisbio.com**](mailto:founders@erisbio.com)", "url": "https://www.ycombinator.com/launches/KM7-eris-biotech-developing-drugs-that-reawaken-the-immune-system-to-kill-cancer", "votes": 186, "created_at": "2024-02-07T21:04:37.925Z" } ] }, { "id": 29485, "name": "Granza Bio", "slug": "granza-bio", "former_names": [ "Zyme Therapeutics" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/e4fe5f43800f16c0ca16303f58b955037e3f2bc1.png", "website": "https://www.granzabio.com/", "all_locations": "San Francisco, CA, USA", "long_description": "Granza Bio is developing programmable therapeutics for the immune system. Our platform is built on the foundational discovery of immune “superkiller” attack particles — the natural ammunition used by cytotoxic immune cells to deliver potent, localized killing. By re-arming exhausted immune cells with newly programmed ammunition, Granza restores and enhances immune function. This approach enables a new class of treatments with the potential to transform diseases ranging from cancer to autoimmunity. ", "one_liner": "Building programmable therapeutics for the immune system", "team_size": 8, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1709082658, "tags": [ "Synthetic Biology", "Biotech", "Healthcare", "Therapeutics", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Winter 2024", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/granza-bio", "api": "https://devasheeshg.github.io/yc-api/batches/winter-2024/granza-bio.json", "year_founded": 2024, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/101140973/", "x_url": "https://twitter.com/GranzaBio", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/e4fe5f43800f16c0ca16303f58b955037e3f2bc1.png", "app_video_url": null, "dday_video_url": null, "company_photos": [ "https://bookface-images.s3.us-west-2.amazonaws.com/attachments/951f3c1e19296f2e20fadafd3714fde2998a701f.png" ], "primary_partner": { "name": "Jared Friedman", "url": "https://www.ycombinator.com/people/jared-friedman" }, "founders": [ { "user_id": 1718918, "full_name": "Ashwin Nandakumar", "title": "Founder/CEO", "founder_bio": "Ashwin completed his PhD (DPhil) in Oncology at the University of Oxford. After completing his PhD, he began working as a Cancer Research UK post-doctoral researcher at Oxford University and also at the Institute of Cancer Research (ICR), London. He also brings experience setting up oncology clinical trials and working in oncology start-ups. ", "is_active": true, "linkedin_url": "https://linkedin.com/in/ashwin-nandakumar-menon", "x_url": "https://twitter.com/Menon_Ashwin", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/abf1515406e6713ee0ab505431bf72dd815baad6.jpg" }, { "user_id": 1720525, "full_name": "Ashwin Jainarayanan", "title": "Founder", "founder_bio": "Granza Bio, DPhil (PhD) in Interdisciplinary Bioscience - University of Oxford\n\n", "is_active": true, "linkedin_url": "https://linkedin.com/in/jainarayananak", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/d8cf072b7b583aa501ae03f0113abf686b2e0b73.jpg" } ], "jobs": [], "news": [ { "title": "Granza Bio grabs $7M seed from Felicis and YC to advance delivery of cancer treatments | TechCrunch", "url": "https://techcrunch.com/2024/07/03/granza-bio-grabs-7m-seed-from-felicis-and-yc-to-advance-delivery-of-cancer-treatments/", "date": "Jul 03, 2024" } ], "launches": [ { "id": 78838, "title": "🎯🦠 Granza Bio – Cancer targeting attack particles derived from our body’s immune system", "tagline": "We engineer \"attack particles\" that selectively target and kill cancer cells, eliminating unwanted side effects and toxicity.", "body": "**Tl;dr:** We are [Granza Bio](https://www.linkedin.com/company/granza-bio-yc-w24/), two PhD graduates in Oncology and Immunology from the University of Oxford on a mission to develop personalised and targeted cancer treatments. We are working on a new weapon in our immune system’s arsenal – “[**attack particles**](https://www.science.org/doi/10.1126/science.aay9207)”. We are turning this concept into a therapeutic product that can eliminate any cancer without harming the surrounding healthy cells, preventing adverse side effects.\n\nHey everyone, we are (Ashwin)²\n\n![uploaded image](/media/?type=post&id=78838&key=user_uploads/1718918/c608a07f-d480-40c7-bb19-16fc620b9666)\n\n# **Team**\n\n🧑🏾[Ashwin Jainarayanan](https://www.linkedin.com/in/jainarayananak/) – Clarendon Scholar and Synthetic Immunologist with extensive research experience on attack particles derived from immune cells.\n\n 🧑🏾[Ashwin Nandakumar](https://www.linkedin.com/in/ashwin-nandakumar-menon/) – Cancer biologist specializing in immuno-oncology, who has previously set up clinical trials and brings extensive Oncology start-up experience.\n\n👨🏻‍🔬 [Mike Dustin](https://www.kennedy.ox.ac.uk/team/michael-dustin) – Professor of Molecular Immunology at the University of Oxford. Widely recognised for his work on immunological synapses and discovered attack particles.\n\n# **❌ Problem:**\n\n\\~50% of cancer patients receive treatments that are (1) ineffective and (2) lead to unwanted and avoidable side effects.\n\n**(1) _High mortality rates:_** Ineffective treatments lead to cancer relapse and ultimately, increased likelihood of dying from cancer. Five-year survival rates are lower than 5% for patients with late-stage cancers including lung, pancreas, and brain cancer.\n\n**(2) _Toxicity and adverse side effects_**: While emerging treatments such as immunotherapy and CAR-T cell therapy are effective in some patients, they also impact their healthy tissues. This causes high toxicity and adverse side effects.\n\n# **✅ Solution: Granza Bio’s cancer-targeting attack particles**\n\nWe have identified **attack particles** ⚡: a powerful suite of weapons in our immune system’s arsenal. These attack particles carry proteins like **_granzymes_** and **_perforins_** that instantly kill cancer cells.\n\n[Watch how it works!](https://www.youtube.com/watch?v=f5IPz1YaAiE&ab_channel=AshwinMenon)\n\n# **📋 Factfile: Granza Bio’s attack particles**\n\n* **💀 High cancer-killing efficacy** in brain, ovarian, lung, and skin cancers.\n* ⚙ Engineered to target **only the cancer cells**, leaving the surrounding healthy cells untouched, meaning no toxicity or adverse side effects.\n* 🧠 Capable of targeting **brain cancers** by crossing the blood-brain barrier.\n* **🎯** Perfectly suited to a **platform approach** meaning we can use attack particles to target a great range of diseases including cancers, autoimmune diseases, and infections.\n* 🏭 **Highly stable** and easy to manufacture.\n\n**Lock & Key method – attack particle targeting cancer**\n\n# \n\n![uploaded image](/media/?type=post&id=78838&key=user_uploads/1718918/0fcc26f3-2645-4d78-aee9-8287c2e707c2)\n\n# **🙏 Our Asks:**\n\n* Share this post with your network and help spread the word!\n* If you’re as excited as we are about this novel approach to eradicating cancer and would like to learn more about what we’re doing, email us at [founders@granzabio.com](mailto:founders@granzabio.com)", "url": "https://www.ycombinator.com/launches/KVa-granza-bio-cancer-targeting-attack-particles-derived-from-our-body-s-immune-system", "votes": 762, "created_at": "2024-02-28T01:19:33.419Z" } ] }, { "id": 29714, "name": "Kopra Bio", "slug": "kopra-bio", "former_names": [ "GlioTx" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/acdb0c2a3124d9e5717a63d0231af9b6f7447919.png", "website": "https://kopra.bio", "all_locations": "San Francisco, CA, USA", "long_description": "Kopra Bio makes genetically engineered viruses that teach your immune system to kill cancer using tech we developed at UCSF. We’re making the next Keytruda ($25B/yr cancer drug blockbuster) starting with the most aggressive form of brain cancer, glioblastoma. In the most challenging brain cancer model, we improve survival from 0% with the current FDA approved treatment to 90% with our treatment.", "one_liner": "Genetically engineered viruses that teach your immune system to kill…", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Therapeutics", "launched_at": 1724130421, "tags": [ "Gene Therapy", "Synthetic Biology", "Biotech", "Therapeutics", "Oncology" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2024", "status": "Active", "industries": [ "Healthcare", "Therapeutics" ], "regions": [ "United States of America", "America / Canada", "Remote", "Partly Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/kopra-bio", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2024/kopra-bio.json", "year_founded": 2024, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/kopra-bio", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/acdb0c2a3124d9e5717a63d0231af9b6f7447919.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Ankit Gupta", "url": "https://www.ycombinator.com/people/ankit-gupta" }, "founders": [ { "user_id": 2206641, "full_name": "Alexander Haddad", "title": "Founder", "founder_bio": " Neurosurgery resident @ UCSF, scientific co-founder @ Kopra Bio. Published over 70 peer-reviewed publications as a neurosurgery resident at UCSF. Alex is particularly interested in the delivery of cell and gene therapies to the central nervous system and neuro-oncology. Kopra Bio is a serial biotech entrepreneur and a UCSF Neurosurgery resident on a mission to revolutionize cancer treatment. ", "is_active": true, "linkedin_url": "www.linkedin.com/in/alexander-haddad-49b484305", "x_url": "https://x.com/AF_Haddad", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/93c5301fb0091307b0055844275d81efd5a9a3b4.jpg" } ], "jobs": [], "news": [], "launches": [ { "id": 83219, "title": "🔬🧠🧬 Kopra Bio - Making cancer cures using viral immunotherapy", "tagline": "Stealthy viruses that teach your immune system to kill cancer.", "body": "**Tl;dr**: We are [Kopra Bio](https://www.linkedin.com/company/kopra-bio), a serial biotech entrepreneur and a UCSF Neurosurgery resident on a mission to revolutionize cancer treatment. Kopra Bio is curing cancer using viral immunotherapy technology we developed at UCSF. We’re making the next Keytruda, a **$25B/yr cancer drug blockbuster**, starting with the most aggressive form of brain cancer, glioblastoma. In preclinical models, we improve survival rates from 0% with standard-of-care treatment to **greater than 90% survival with our treatment.**\n\n**—**\n\nHey - we are Andrew and Alex!\n\n![uploaded image](/media/?type=post&id=83219&key=user_uploads/214420/8312b484-2aee-4ae8-bd7b-bc708051b7d1)\n\n# **Team:**\n\n🤵 [**Andrew Bartynski, PhD**](https://www.linkedin.com/in/andrewbartynski/) - Serial Biotech Entrepreneur and **repeat YC founder**. Developed the **contraceptive pill for men** as COO @ YourChoice Therapeutics (YC W19). Founded a **COVID-19 antiviral** company that went from founding to Phase II/III clinical trial in < 6 months and was acquired in < 1 year as COO @ ANA Therapeutics. Made **next-generation psychedelics** for mental health @ Alexander Shulgin Research Institute. Now curing cancer as CEO @ Kopra Bio.\n\n👨‍⚕️[**Alexander Haddad, MD**](https://www.linkedin.com/in/alexander-haddad-49b484305/) - Scientific Cofounder @ Kopra Bio, Neurosurgery Resident @ UCSF. Alex **published >** **70 peer-reviewed publications as a neurosurgery resident at UCSF**. He is particularly interested in **neuro-oncology** and the delivery of cell and **gene therapies** to the central nervous system. Alex helped spearhead the development of Kopra Bio’s viral technology in the labs of Dr. Manish Aghi and Dr. Noriyuki Kasahara. His clinical skills have also been recognized with the Krevans Award for clinical excellence at San Francisco General Hospital.\n\n👨‍⚕️ [**Manish Aghi, MD, PhD**](https://www.ucsfhealth.org/providers/dr-manish-aghi) - Neurosurgeon and Professor @ UCSF. Renowned expert with over **30 years of experience in Neurosurgery and tumor microenvironment** leading the Brain Tumor Research Center at UCSF with a focus on malignant brain tumors like glioblastoma.\n\n👨‍⚕️ [**Noriyuki Kasahara, MD, PhD**](https://braintumorcenter.ucsf.edu/people/noriyuki-kasahara) - CSO @ 4D Molecular Therapeutics, Professor of Neurological Surgery and Radiation Oncology @ UCSF. Dr. Kasahara has been a **world leader** in the field of **cancer research and gene therapy vector** **development** for over 30 years.\n\n**👩‍🔬** **Sara Collins, PhD** - Gene Therapy Specialist @ UCSF, Director @ 4D Molecular Therapeutics. World expert in the development of **vectors for cancer gene therapy**.\n\n# How do we get to a world without cancer?\n\n# **❌ Today’s approach** - death by a thousand cuts\n\nState-of-the-art cancer therapies target tumor mutations one by one. Despite more than 550 cancer drug approvals since the year 2000, there are still 10 million cancer deaths each year. This approach is expensive (**$1B per therapy**), slow (**10 years of development** per drug), and incremental (only **one mutation addressed** per therapy). Even the most successful cancer drugs of all time have **success rates of less than 10% in solid tumors**.\n\n# **✅ Kopra Bio’s Solution** - first principles approach that targets phenotypes seen across all cancers\n\nUsing **stealthy viruses🦠**, Kopra Bio infects cancer cells, spreads throughout tumors, and hijacks them to produce immune signals. The immune signals recruit T cells which then kill the cancer. This process teaches the patient’s immune system to kill their tumor - _in vivo_ - **curing the cancer and eliminating metastasis and recurrence.**\n\n![uploaded image](/media/?type=post&id=83219&key=user_uploads/214420/71da663f-8b6a-41da-81bf-179a4cddb385)\n\n# **🔬Kopra Bio at a glance**\n\n* **Demonstrated efficacy** in the most challenging brain cancer models increasing survival from 0% without treatment to **greater than 90% survival** with our treatment\n* **Cancer selective** by design - reduced toxicity and adverse events\n* **Platform** approach broadly applicable across cancer\n* Strong **safety** profile\n* Highly stable and **scalable** to manufacture\n\n# **🙏 Asks**\n\n* Share this post on your socials and help spread the word!\n* If you’re as excited as we are about eradicating cancer and would like to learn more about what we’re doing, **email us** at [founders@kopra.bio](mailto:founders@koprabio.com)", "url": "https://www.ycombinator.com/launches/LeF-kopra-bio-making-cancer-cures-using-viral-immunotherapy", "votes": 201, "created_at": "2024-08-20T15:08:44.470Z" } ] }, { "id": 32623, "name": "Omanta", "slug": "omanta", "former_names": [ "ClinSIGHT AI" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/ae1812a6e6a806880355a25e542d3970bd58deb5.png", "website": "https://omanta.com/", "all_locations": "San Francisco, CA, USA", "long_description": "Omanta is a personalized research lab for patients who have exhausted standard options, want to prepare proactively for recurrence, or are living with an unresolved diagnosis.\r\n\r\nWe direct the full operational infrastructure, personnel, expertise, and technology of a large research program toward understanding and addressing the challenges of individual patients across oncology, rare disease, and undiagnosed conditions.\r\n\r\nFor clinicians, we act as a collaborative partner, providing a living roadmap for ongoing patient care built on a rigorous and evolving scientific evidence base.\r\n\r\nWe fully operationalize patient-specific research programs, covering tissue logistics, diagnostic follow-up, data integration, multiomic analysis, therapeutic strategy development, and more.\r\n\r\nOmanta brings context and clarity to complex cases, helping clinicians see more of the scientific picture as they decide how best to care for their patients.", "one_liner": "A research lab for one", "team_size": 6, "industry": "Healthcare", "subindustry": "Healthcare", "launched_at": 1785793252, "tags": [ "Digital Health", "Healthcare", "Health & Wellness", "Oncology", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2026", "status": "Active", "industries": [ "Healthcare" ], "regions": [ "United States of America", "America / Canada" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/omanta", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2026/omanta.json", "year_founded": 2026, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/omanta/", "x_url": "https://x.com/Omantahealth", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/ae1812a6e6a806880355a25e542d3970bd58deb5.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Diana Hu", "url": "https://www.ycombinator.com/people/diana-hu" }, "founders": [ { "user_id": 3670159, "full_name": "Alfredo Gonzalez", "title": "Founder/CEO", "founder_bio": "Co-Founder and CEO of Omanta. PhD in Cancer Bioinformatics from UCLA, biomedical researcher at Broad Institute and Harvard. Spearheaded personalized therapeutic campaigns for patients creating personalized vaccines, immunotherapies, and radioligands. 10+ years in personalized medicine. Fueled by the belief that the future of Health is deeply personalized.\n\n", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/alfredo-gonzalez-phd/", "x_url": "", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/9d5790791f1a19912cd701c3817cb00d66003eca.jpg" }, { "user_id": 3399110, "full_name": "Ranad Humeidi", "title": "Founder and Chief Scientific Officer", "founder_bio": "Co-founder & CSO at Omanta, working with patients to turn frontier science into personalized treatment strategies. Harvard Chemical Biology PhD in 3 years; identified a druggable ulcerative colitis mechanism that led to a multimillion-dollar GSK collaboration. Built and directed a multimillion-dollar rare cancer program for one patient, coordinating researchers, physicians, biotechs, and drug developers. Led strategies for 12+ complex patients after standard options were exhausted.\n", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/rhumeidi", "x_url": "https://x.com/Ranadhumeidi", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/4e2478bf2c078b78d7428a780e36bd00d7bba74a.jpg" } ], "jobs": [], "news": [], "launches": [ { "id": 108925, "title": "Omanta: A personal research lab dedicated to each patient.", "tagline": "A research lab, for one.", "body": "Hey YC! We're Alfredo and Ranad, the founders of Omanta.\n\n**TL;DR: Omanta creates a personalized research lab around a single patient. We integrate a patient’s complete medical record, personal genomics, and use AI to take on the most complex cancer cases. Our researchers tackled GitLab co-founder Sid Sijbrandij’s case, helping bring him into complete remission.**\n\n\n\n\\\n**Why this matters**\\\nIf you're a cancer patient, you'd think the hardest cases have entire teams dedicated to solving them. The reality: most doctors have about 20 minutes per patient, while the science never stops moving. New discoveries emerge every day, yet reaching standard clinical care can take over a decade (\\~17 years on average). Physicians make high-stakes decisions with limited time, and even the most difficult cases rarely have anyone whose full-time job is to interrogate every layer of that one patient's disease and push the newest science toward their treatment.\n\nThat's the gap we built Omanta to close.\\\n\\\n**What we do**\\\nWe meet patients wherever they are in their journey. We integrate their complete medical record and personal genomics with AI and clinical evidence to understand the molecular drivers of their disease. Then we map every existing therapy against their biology, and if the right therapy doesn't exist, we build it, from cancer vaccines and immunotherapies to highly targeted radioligand therapies.\\\n\\\nWe've worked on some of the most complex cancer cases in the world. Most notably, **Alfredo was the genomics lead for the personalized therapeutic campaign behind GitLab founder Sid Sijbrandij's complete remission**, partnering with leading institutions to pursue personalized mRNA/DNA vaccines, CAR-T programs, drug repurposing, expanded-access therapies, and continuous molecular monitoring. We've seen what becomes possible when the full force of modern science is organized around a single person, and Omanta brings that depth of investigation to every case.\\\n\\\n**Why us**\\\nWe met eight years ago working on early CRISPR cancer research and have been building toward this ever since.\n\n* **Alfredo Gonzalez, PhD (CEO)** — translational genomics. Led the year-long investigation of 25TB of sequencing and molecular data for Sid Sijbrandij, key missing information in existing genomic reports, and uncovered actionable findings that reshaped his therapeutic strategy, including personalized mRNA/DNA vaccines, CAR-T, expanded access, drug repurposing, and continuous monitoring. PhD at UCLA, where he built one of the world's largest centralized multi-omic datasets for rare tumors. Previously at the Broad Institute (Cancer Dependency Map, validating targets from large-scale CRISPR screens) and Harvard's Wagers Lab.\n* **Ranad Humeidi, PhD (CSO)** — chemical biologist. Earned her PhD in Chemical Biology from Harvard in three years, where she identified a druggable mechanism in ulcerative colitis that became the basis of a multimillion-dollar GSK collaboration. Built and directed a multimillion-dollar scientific program centered on a single rare-cancer patient, then went on to direct scientific strategy for 12+ medically complex patients after standard options were exhausted. At the Broad, she co-created and co-led a fellowship turning scientific discoveries into companies.\n\n\\\n**Our ask**\n\n* Intros. If you or someone you love is facing a difficult cancer diagnosis, we want to hear from you.\n* We're also looking to connect with physicians who want a dedicated research team behind their most complex cases.\n* Reach us here on Bookface or at [alfredo@omanta.com](mailto:alfredo@omanta.com) & [ranad@omanta.com](mailto:ranad@omanta.com).\n\n[omanta.com](http://omanta.com)\\\nA research lab, for one.", "url": "https://www.ycombinator.com/launches/SKr-omanta-a-personal-research-lab-dedicated-to-each-patient", "votes": 73, "created_at": "2026-08-04T13:31:15.555Z" } ] }, { "id": 33016, "name": "Gamgee", "slug": "gamgee", "former_names": [ "Gamgee Technologies" ], "small_logo_thumb_url": "https://bookface-images.s3.amazonaws.com/small_logos/6f6bf83f60f82f47f1a3b961153608810edebb3b.png", "website": "https://gamgee.io/", "all_locations": "San Francisco, CA, USA; Remote", "long_description": "​Gamgee began with Rosie, founder Paul Conyngham’s dog. After surgery, chemotherapy and immunotherapy failed, Rosie was given months to live. Paul used AI and genomic analysis to identify targets in her tumour, then worked with scientists at UNSW to produce what is believed to be the first fully computationally designed mRNA cancer vaccine delivered to a dog. Following treatment, several tumours shrank significantly and her quality of life improved\r\n\r\nGamgee is building an end to end platform for personalised mRNA cancer vaccines for dogs. We sequence a dog’s tumour and healthy DNA, identify mutations unique to its cancer, and design a vaccine that teaches the immune system what to attack. We manage the entire process- from vet intake and tissue collection through genomic analysis, vaccine production, treatment and response monitoring\r\n\r\n​We are now turning that one off effort into a repeatable clinical system. Gamgee is running clinical trials in Australia, working with vets, oncologists and specialised laboratories, and accepting cases globally. Our goal is to make personalised cancer treatment accessible to every dog that needs it- and use each case to improve the treatment for the next", "one_liner": "Curing cancer. Starting with dogs.", "team_size": 2, "industry": "Healthcare", "subindustry": "Healthcare -> Drug Discovery and Delivery", "launched_at": 1784748212, "tags": [ "Biotech", "Genomics", "Oncology", "AI" ], "tags_highlighted": [], "top_company": false, "isHiring": false, "nonprofit": false, "batch": "Summer 2026", "status": "Active", "industries": [ "Healthcare", "Drug Discovery and Delivery" ], "regions": [ "United States of America", "America / Canada", "Remote", "Fully Remote" ], "stage": "Early", "app_video_public": false, "demo_day_video_public": false, "app_answers": null, "question_answers": null, "url": "https://www.ycombinator.com/companies/gamgee", "api": "https://devasheeshg.github.io/yc-api/batches/summer-2026/gamgee.json", "year_founded": 2026, "city": "San Francisco", "country": "US", "linkedin_url": "https://www.linkedin.com/company/109672135", "x_url": "", "fb_url": null, "cb_url": null, "github_url": null, "logo_url": "https://bookface-images.s3.amazonaws.com/small_logos/6f6bf83f60f82f47f1a3b961153608810edebb3b.png", "app_video_url": null, "dday_video_url": null, "company_photos": [], "primary_partner": { "name": "Tyler Bosmeny", "url": "https://www.ycombinator.com/people/tyler-bosmeny" }, "founders": [ { "user_id": 564809, "full_name": "Paul Conyngham", "title": "Founder/CEO", "founder_bio": "Founder at Gamgee Technologies (YC S26), building personalised mRNA cancer vaccines for dogs.\n\nGamgee grew out of my work using AI and genomics to help my dog Rosie fight cancer. \n\nPreviously co-founded Core Intelligence, building applied AI systems across startups and enterprise, and helped grow Australia’s AI community as a founding member of the Data Science & AI association of Australia. \n\nBackground in ML, data science and electrical and computer systems engineering", "is_active": true, "linkedin_url": "https://www.linkedin.com/in/paustevenlconyngham/", "x_url": "https://x.com/paul_conyngham", "avatar_thumb_url": "https://bookface-images.s3.us-west-2.amazonaws.com/avatars/4fda91993052b2e444cfffa9d59e27aa42567028.jpg" } ], "jobs": [], "news": [], "launches": [ { "id": 109527, "title": "Gamgee: Personalised mRNA cancer vaccines for dogs", "tagline": "Input the tumour. Output the vaccine. 300+ dogs on the waitlist.", "body": "**We believe that AI meets biology is the biggest opportunity of the 21st century.** We are using AI to build autonomous systems that read biological failure, discover how to control it, and design precise repairs. We are starting with the first computationally personalised mRNA cancer vaccine for dogs.\\\n\\\n**My dog Rosie was dying of cancer.** I designed her an mRNA vaccine. Several of her tumours shrank 50-75%. I am not a biologist - I spent 17 years in machine learning. Doing it by hand took a year and around $20,000. Gamgee is turning that process into software. Our target is a vaccine design in 48 hours and an end-to-end cost of $2,000\n\n\n\n**How it works**\n\n* We **send you a collection kit** to take to your vet or veterinary oncologist. Your vet collects the tumour and matched healthy samples, which are returned for DNA and RNA sequencing.\n* Our software finds and ranks the mutations worth targeting, and keeps the evidence behind every call.\n* **Out comes an mRNA vaccine** design ready for manufacture. Gamgee designs the vaccine and oversees and coordinates every step through to administration by the treating veterinarian.\n\n\\\n**The market**\n\nApproximately **six million dogs** are **diagnosed with cancer** every year in the United States, and cancer is the leading cause of death in adult dogs. Owners who pursue specialist treatment spend thousands on surgery, chemotherapy and radiation.\\\n\\\n\\\n**The compounding data advantage**\n\nEvery dog we treat returns sequencing, immune and outcome data for a species where datasets remain scarce. That data improves target selection, which improves the next vaccine, which produces better data. We are not just early to the problem - we are the ones accumulating the data that solves it.\n\n\\\n**Proof so far**\n\n* Full computational pipeline built and executed end-to-end as a non-biologist using AI\n* 50-75% shrinkage in the responsive tumours. \n* Microscopic analysis found substantial IBA1+ macrophage and CD3+ T-cell infiltration in Rosie’s responsive lesions, with little in the non-responsive tumour.\n* Second-generation vaccine completed and ready\n* Over a billion impressions on Rosie's story.\n* Backed by Y Combinator (S26) \n\nRosie was one patient. Our next step, already well underway, is a clinician-led trial in 30 dogs to evaluate safety, immune response and clinical outcomes.\n\n\\\n**Why dogs first, and not only dogs**\n\nMost modern dog breeds were created within the last few hundred years from small founder populations and then bred within closed gene pools. This concentrates inherited cancer risk, leaving many breeds unusually prone to particular cancers.\\\n\\\nPet dogs develop cancer naturally, not in a laboratory. Their immune systems are intact and their disease progresses on timelines that let us learn quickly. Dogs are a real market in their own right and the fastest place to get good at personalised cancer vaccines.\n\n\\\n**Our ask**\n\n* **If your dog has cancer, please do get in touch about our upcoming clinical trial.**\n* Veterinary oncologists and specialty hospitals who want to be a trial site.\n* Investors in longevity or personalised medicine - would rather meet you before the trial reads out than after.\n\nWe are building Gamgee so that no other dog waits for hope which arrives too late.\n\nReach me at [paul@gamgee.io](mailto:paul@gamgee.io) or [gamgee.io](http://gamgee.io)\\\n\\\nI love you Rosie.", "url": "https://www.ycombinator.com/launches/SUZ-gamgee-personalised-mrna-cancer-vaccines-for-dogs", "votes": 186, "created_at": "2026-08-11T17:00:00.187Z" } ] } ]